The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Interim Results From Phase 2b Trial Are 'Encouraging'

Research Report
  ()
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.

Biopharma Asks for Emergent Use in US of New COVID Drug

Research Report
  ()
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report.

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating

Research Report
  ()
To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report.

Analyst Says Buy Before Biotech Co.'s Clinical Trials

Research Report
  ()
Argenx SE has "several upcoming catalysts," noted a Wedbush report.

Important Catalyst Expected Soon for Cancer Drug Co.

Research Report
  ()
The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.

Dermatology Co.'s Target Price Much Higher Than Current

Research Report
  ()
The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report.

Second Trial of New Eczema Drug To Commence in Q4/22

Research Report
  ()
The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.

Price Target on US Biopharma Co. Boosted by $15

Research Report
  ()
The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report.

New Drug Shown To Help Patients With Desmoid Tumors

Research Report
  ()
This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report.

Co. Advancing Drug Class With Broad Potential

Research Report
  ()
This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report.

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'

Contributed Opinion
  ()
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet

  ()
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run.

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise

Research Report
  ()
Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report.

US Co. To Regain All Rights to Its AGHD Diagnostic Test

Research Report
  ()
This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report.

Biopharma Co. Transforming Injected Drugs Into Pills

Research Report
  ()
This Israeli firm recently attracted the attention of the US-based financial institution, H.C. Wainwright & Co., which launched analyst coverage of it.

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling

Contributed Opinion
  ()
Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen.

Two Talks On New Cancer Drug Slated for Meeting This Week

Research Report
  ()
The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report.

Showing Results: 1 to 25 of 145 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe